Entrada Therapeutics
| General Information | |
| Business: | We aim to transform the lives of patients by establishing Endosomal Escape Vehicle (EEV) therapeutics as a new class of medicines and we aim to become the world’s foremost intracellular therapeutics company. EEV therapeutics are comprised of small cyclic peptides that are chemically conjugated to a wide range of specific and active biological therapeutics. Our EEV therapeutics are designed to engage intracellular targets that have long been considered inaccessible and undruggable. Through our proprietary EEV Platform, we are building a robust development portfolio of EEV therapeutic candidates. We believe that the potential success of our early programs will allow us to build portfolios in rare disease, immunology and oncology.
We are initially focused on the development of EEV therapeutics for rare neuromuscular diseases, including Duchenne muscular dystrophy (DMD) and myotonic dystrophy type 1 (DM1). DMD is caused by genetic mutations that prevent the creation of functional dystrophin, a protein required to maintain the structural integrity of muscle cells. Our most advanced therapeutic candidate, ENTR-601-44, is being developed for patients with DMD. We plan to submit an Investigational New Drug (IND) application to the U.S. Food and Drug Administration (FDA) for ENTR-601-44 in 2022. We are developing a second lead program for patients with DM1. We plan to submit an IND to the FDA for an EEV-PMO candidate to treat DM1 in 2023.
(Entrada Therapeutics priced its IPO on Oct. 28, 2021, at $20 – the mid-point of its $19-to-$21 range – and increased the number of shares to 9.08 million (9,075,000), up from 7.5 million in the prospectus, to raise $181.5 million.)
|
| Industry: | PHARMACEUTICAL PREPARATIONS |
| Employees: | 78 |
| Founded: | 2016 |
| Contact Information | |
| Address | 6 Tide Street Boston, MA 02210 |
| Phone Number | (857) 520-9158 |
| Web Address | http://www.entradatx.com/ |
| View Prospectus: | Entrada Therapeutics |
| Financial Information | |
| Market Cap | $566.24mil |
| Revenues | $0 mil (last 12 months) |
| Net Income | $-33.94 mil (last 12 months) |
| IPO Profile | |
| Symbol | TRDA |
| Exchange | NASDAQ |
| Shares (millions): | 9.1 |
| Price range | $20.00 - $20.00 |
| Est. $ Volume | $181.5 mil |
| Manager / Joint Managers | Goldman Sachs/ Cowen and Company/ Evercore |
| CO-Managers | - |
| Expected To Trade: | 10/29/2021 |
| Status: | Priced |
| Quiet Period Expiration Date: | Available only to Subscribers |
| Lock-Up Period Expiration Date: | Available only to Subscribers |
| SCOOP Rating | Available only to Subscribers |
| Rating Change | Available only to Subscribers |